-
Lymphoma Roundtable · ASH Special | Professor Cai Qingqing: New Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma
The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) has recently concluded successfully in Orlando, USA. As the “grand finale” of the hematology field each year, this meeting showcased a series of cutting-edge breakthroughs in lymphoma research, providing new directions for optimizing clinical practice.
-
Voice of China at ASH | Professor Zou Dehui: With Early Prediction and Patient Selection, CAR-T Therapy Will Deliver Greater Value in R/R DLBCL
From December 6–9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the world’s largest and most influential international conference in hematology, ASH attracts tens of thousands of experts and scholars each year to share the latest advances and breakthrough research in the field.
-
Global Perspectives at ASH |Professor Othman Al-Sawaf: The CLL17 Trial Redefines the Treatment Paradigm—Fixed-Duration Therapy Is Non-Inferior to Continuous Treatment
The widespread adoption of targeted therapies has significantly improved long-term outcomes for patients with chronic lymphocytic leukemia (CLL). However, a critical question has remained unanswered: Is fixed-duration therapy as effective as continuous treatment? Until now, no prospective head-to-head evidence had directly compared these two strategies.
-
Lymphoma In-Depth Conversations · ASH Special | Professor Qingqing Cai: New Advances in First-Line Treatment of Follicular Lymphoma
The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) has recently concluded in Orlando, USA. As the “year-end flagship event” in hematology, this year’s meeting presented a…
-
Prof. Wojciech Jurczak on the BRUIN CLL-313 Study and First-Line CLL Treatment
In this video from ASH, Prof. Wojciech Jurczak, consultant hematologist and Head of Department at the Maria Skłodowska-Curie National Research Institute of Oncology, shares key results from the randomized BRUIN…
-
Prof. Othman Al-Sawaf on Fixed-Duration vs Continuous Therapy in CLL
In this video, Prof. Othman Al-Sawaf, hematologist and clinical investigator at the University Hospital Cologne and the German CLL Study Group, shares key findings from a randomized study comparing fixed-duration…
-
ASH China Voice | Deyan Liu / Xiaomei Liu: Allogeneic HSCT Improves Outcomes in SET::CAN–Positive Hematologic Malignancies
From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the largest and most influential international conference…
-
ASH Global Perspectives | Smart Immune Cell Redirection: SITE Offers a Novel Therapeutic Solution for Multiple Myeloma
Multiple myeloma (MM) is a malignant hematologic tumor originating from plasma cells. Despite significant advances in available therapies, disease relapse and drug resistance remain major barriers to achieving a cure.…
Connecting Medical Expertise through Media